Table 4. Cost-of-illness analyses–Costs in categories and total costs per patient per year (in 2015 US$-PPP).
| Reference | Time horizon | Hospital care costa | Outpatient care cost | Medication costs | Nursing care costs | Overall direct costsb | CRCP-specific costs |
|---|---|---|---|---|---|---|---|
| Alemayehu et al. [74] | Varying1 | 17,121 | 25,052 | 3,993 | − | 47,465 | 24,348 |
| Known CRPC | 15,835 | 28,598 | 4,683 | − | 50,537 | 30,412 | |
| Likely CRPC | 17,324 | 24,538 | 3,898 | − | 47,018 | 23,468 | |
| Armstrong et al. [75] | 24 months | ||||||
| Medicare | 7,362 | 6,927 | 12,802 | 1,248 | 28,792 | − | |
| MarketScan | 10,109 | 19,827 | 36,864 | 490 | 67,957 | − | |
| Bourke et al. [76] | 12 months | − | − | − | − | − | 77,725 |
| Bryant-Lukosius [77] | 12 months | 1,698 | 1,840 | 3,425 | 550 | 7,514 | − |
| Bui et al. [78] | Varying1 | ||||||
| With CSS | 4,286 | 29,323 | 24,962 | − | 59,799 | − | |
| W/o CSS | 14,499 | 31,604 | 24,148 | − | 71,742 | − | |
| Dragomir et al. [79] | Lifetime | ||||||
| ADT+DX+A treatment | − | − | − | − | − | 17,441 | |
| ADT+DX+CX treatment | − | − | − | − | − | 28,242 | |
| Engel-Nitz et al. [80] | Varying2 | ||||||
| Oncologist patient | 22,364 | 41,170 | 5,314 | − | 70,627 | 47,647 | |
| Urologist patient | 17,670 | 11,240 | 3,578 | − | 33,918 | 14,335 | |
| Krahn et al. [81] | Varying3 | ||||||
| CRPC | 14,543 | 4,491 | 6,022 | 433 | 25,490 | − | |
| mCRPC | 19,243 | 5,482 | 9,810 | 1,475 | 36,010 | − | |
| Kunisawa et al. [82] | Varying1 | − | − | − | − | 17,921 | − |
| Malmberg et al. [83] | Varying4 | ||||||
| Within country | 3,743 | 520 | − | − | − | 4,996 | |
| Out of country | 6,725 | 507 | − | − | − | 7,827 | |
| Mehra et al. [84] | Varying1 | ||||||
| Pre-DX period | 8,960 | 18,408 | 5,125 | − | − | 32,494 | |
| Post-DX period | 23,308 | 25,614 | 24,323 | − | − | 73,270 | |
| Organ et al. [85] | 24 months | ||||||
| Intermittent LHRHa | − | − | − | − | 2,474 | − | |
| Continuous LHRHa | − | − | − | − | 6,514 | − | |
| Sanyal et al. [86] | Lifetime | − | − | − | − | − | 3,067 |
| Satoh et al. [55] | Varying5 | ||||||
| ICD-10 | 611c | − | 6,183c | − | − | 6,794c | |
| MEDIC-DC | 1,183c | − | 19,935c | − | − | 21,118c | |
| Sherman et al. [87] | 6 months | − | − | − | − | 31,683 | − |
| S89 treatment | − | − | − | − | 26,707 | − | |
| V+E treatment | − | − | − | − | 28,216 | − | |
| V+E+S89 treatment | − | − | − | − | 51,162 | − |
ADT: androgen deprivation therapy, CRCP: castration-resistant prostate cancer, CSS: corticosteroid-sensitive comorbidities, CX: cabazitaxel, DX: docetaxel, E: estramustine LHRHa: luteinizing hormone-releasing hormone agonist, mCRPC: metastatic castration-resistant prostate cancer, S89: strontium-89, V: vinblastine, w/o: without.
1 Costs per patient per month were reported
2 costs per patient per 6 months were reported
3 costs per patient per 100 days were reported
4 costs per patient per relapse were reported
5 costs per patient per 12 months were reported
a including costs for emergency department visits
b may include other medical, non-medical or indirect costs not previously listed
c in $-PPP-2016 without inflation.